지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2012.1
- 수록면
- 1,128 - 1,135 (8page)
이용수
초록· 키워드
오류제보하기
Purpose: Mutations in the epidermal growth factor receptor (EGFR) have been confirmed as predictors of the efficacy of treatment with EGFR-tyrosine kinase inhibitors (TKIs). We investigated whether polymorphisms of the EGFR gene were associated with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with EGFR-TKI. Materials and Methods: A polymorphic dinucleotide repeat in intron 1 [CA simple sequence repeat in intron 1(CA-SSR1)] in intron 1 and single nucleotide polymorphisms (SNP-216) in the promoter region of the EGFR gene were evaluated in 71 NSCLC patients by restriction fragment length polymorphism and DNA sequencing. The relationship between genetic polymorphisms and clinical outcomes of treatment with EGFR-TKIs was evaluated. Results:SNP-216G/T polymorphisms were associated with the efficacy of EGFR-TKI. The response rate for the SNP-216G/T tended to be higher than that for G/G (62.5% vs. 27.4%, p=0.057). The SNP-216G/T genotype was also associated with longer progression-free survival compared with the GG genotype (16.7 months vs. 5.1 months, p=0.005). However, the length of CA-SSR1 was not associated with the efficacy of EGFR-TKI. Conclusion: SNP-216G/T polymorphism was a potential predictor of clinical outcomes in NSCLC patients treated with EGFR-TKI.
목차
등록된 정보가 없습니다.
참고문헌 (22)
참고문헌 신청
Amador ML / 2004 / An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors / Cancer Res 64 : 9139 ~ 9143
Cappuzzo F / 2005 / Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer / J Natl Cancer Inst 97 : 643 ~ 655
Fukuoka M / 2003 / Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer(The IDEAL 1 Trial)[corr
Fukuoka M / 2011 / Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxe
Hlinkova K / 2011 / Rapid and efficient detection of EGFR mutations in problematic cytologic specimens by high-resolution melting analysis / Mol Diagn Ther 15 : 21 ~ 29
Cappuzzo F / 2005 / Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer / J Natl Cancer Inst 97 : 643 ~ 655
Fukuoka M / 2003 / Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer(The IDEAL 1 Trial)[corr
Fukuoka M / 2011 / Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxe
Hlinkova K / 2011 / Rapid and efficient detection of EGFR mutations in problematic cytologic specimens by high-resolution melting analysis / Mol Diagn Ther 15 : 21 ~ 29
이 논문의 저자 정보
최근 본 자료
댓글(0)
0